Tandem Diabetes Care (NASDAQ:TNDM) traded higher on Tuesday after Citi upgraded the insulin pump maker to Neutral from Sell, citing a shift in its risk-reward setup following the company’s ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) has been given an average rating of “Moderate Buy” by the seventeen analysts that are presently covering the firm, MarketBeat.com ...

Tandem Diabetes Care has stated it will not update forward-looking statements with new information or future events. This news is based on the company’s recent SEC filing. 3rd party Ad.

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 5.4% in the morning session after the stock appeared to rebound from a recent 52-week low as investors looked ahead ...

Current Tandem pump users will be contacted by Tandem or their current supplies distributor with more information closer to the time of availability. About Tandem Diabetes Care, Inc.

Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $11 from $10.35 and keeps a Neutral rating on the shares. The firm adjusted ...

Tandem Diabetes Care, Inc.TNDM announced the latest real-world insights from a user satisfaction survey on their Tandem Mobi system during the 84th Scientific Sessions of the American Diabetes ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today announced its acquisition of infusion set d ...